Tools for translational epigenetic studies involving formalin-fixed paraffin-embedded human tissue: applying the Infinium HumanMethyation450 Beadchip assay to large population-based studies
Authors:
- Ee Ming WongEWEe Ming Wong
- JiHoon E. JooJJJiHoon E. Joo
- Catriona A. McLeanCMCatriona A. McLean
- Laura BagliettoLBLaura Baglietto
- Dallas R. EnglishDEDallas R. English
- Gianluca SeveriGSGianluca Severi
- John L. HopperJHJohn L. Hopper
- Roger L. MilneRMRoger L. Milne
- Liesel M. FitzGeraldLFLiesel M. FitzGerald
- Graham G. GilesGGGraham G. Giles
- Melissa C. SoutheyMSMelissa C. Southey
Open Access
- 6 October 2015
- journal article
- research article
- Published by Springer Nature in BMC Research Notes
- Vol. 8 (1) , 543
Abstract
Large population-based translational epigenetic studies are emerging due to recent technological advances that have made molecular analyses possible. For example, the Infinium HumanMethylation450 Beadchip (HM450K) has enabled studies of genome-wide methylation on a scale not previously possible. However, application of the HM450K to DNA extracted from formalin-fixed paraffin-embedded (FFPE) tumour material has been more challenging than application to high quality DNA extracted from blood. To facilitate the application of this assay consistently across a large number of FFPE tumour-enriched DNA samples we have devised a modification to the HM450K protocol for FFPE that includes an additional quality control (QC) checkpoint. QC checkpoint 3 was designed to assess the presence of DNA after bisulfite conversion and restoration, just prior to application of the HM450K assay. DNA was extracted from 474 archival FFPE breast tumour material. Five samples did not have a detectable amount of DNA with an additional 42 failing to progress past QC checkpoint 3. Genome-wide methylation was measured for the remaining 428 tumour-enriched DNA. Of these, only 4 samples failed our stringent HM450K data criteria thus representing a 99 % success rate. Using prior knowledge about methylation marks associated with breast cancer we further explored the quality of the data. Twenty probes in the BRCA1 promoter region showed increased methylation in triple-negative breast cancers compared to Luminal A, Luminal B and HER2-positive breast cancer subtypes. Validation of this observation in published data from The Cancer Genome Atlas (TCGA) Network (obtained from DNA extracted from fresh frozen tumour samples) confirms the quality of the data obtained from the improved protocol. The modified protocol is suitable for the analysis of FFPE tumour-enriched DNA and can be systematically applied to hundreds of samples. This protocol will have utility in population-based translational epigenetic studies and is applicable to a wide variety of translated studies interested in analysis of methylation and its role in the predisposition to disease and disease progression.Keywords
This publication has 23 references indexed in Scilit:
- Expanding Epigenomics to Archived FFPE Tissues: An Evaluation of DNA Repair MethodologiesCancer Epidemiology, Biomarkers & Prevention, 2014
- Validation of DNA methylation profiling in formalin-fixed paraffin-embedded samples using the Infinium HumanMethylation450 MicroarrayEpigenetics, 2014
- The use of DNA from archival dried blood spots with the Infinium HumanMethylation450 arrayBMC Biotechnology, 2013
- Constitutional Methylation of the BRCA1 Promoter Is Specifically Associated with BRCA1 Mutation-Associated Pathology in Early-Onset Breast CancerCancer Prevention Research, 2011
- Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 StudiesPLOS Medicine, 2010
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic SubtypesJournal of Clinical Oncology, 2009
- Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumorsEpigenetics, 2008
- Optimizing Annealing Temperature Overcomes Bias in Bisulfite PCR Methylation AnalysisBioTechniques, 2007
- The Melbourne Collaborative Cohort Study.2002
- Isolation and characterisation of the NBR2 gene which lies head to head with the human BRCA1 geneHuman Molecular Genetics, 1997